Genmab A/S
corporate_fare Company Profile
Genmab A/S (NASDAQ:GMAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for GMAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-03, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for GMAB spans 6-K, 20-F.
Recent high-impact activity:
- Genmab's Rina-S Shows 45.9% ORR in Platinum-Resistant Ovarian Cancer
- Genmab Lifts 2026 Outlook After Revenue Surges 25%; Epcoritamab Clears Key Phase 3 Hurdle
- DARZALEX Q2 Sales Hit $4.2B, Up 46% YoY, Boosting Genmab Royalties
- EC Approves Genmab's TEPKINLY for Relapsed/Refractory Follicular Lymphoma, First Bispecific Option
- Epcoritamab Phase 3 Smashes Primary Endpoint, Cuts DLBCL Progression Risk by 60%
Financial Snapshot
Short Interest & Short Volume
3.17 days to coverFINRA reported short interest of 4,920,530 shares in GMAB as of the September 15, 2026 settlement, a 28.0% decrease from the prior period — about 3.2 days to cover at its recent average daily volume. On October 2, 2026, 43.4% of GMAB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
GMAB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.